Inotek Pharmaceuticals Corp. (NASDAQ:ITEK)’s share price was up 4.4% during trading on Tuesday . The company traded as high as $9.00 and last traded at $8.84, with a volume of 256,146 shares changing hands. The stock had previously closed at $8.47.

A number of equities analysts recently weighed in on ITEK shares. HC Wainwright started coverage on shares of Inotek Pharmaceuticals Corp. in a research report on Tuesday. They issued a “buy” rating and a $22.00 price objective on the stock. Piper Jaffray Cos. set a $29.00 target price on shares of Inotek Pharmaceuticals Corp. and gave the stock a “buy” rating in a research report on Wednesday, July 20th.

The stock has a 50-day moving average of $7.08 and a 200-day moving average of $8.11. The stock’s market capitalization is $240.19 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/inotek-pharmaceuticals-corp-itek-trading-up-4-4.html

Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.07. On average, analysts forecast that Inotek Pharmaceuticals Corp. will post ($1.42) earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. purchased a new stake in Inotek Pharmaceuticals Corp. during the second quarter valued at about $207,000. Adage Capital Partners GP L.L.C. raised its stake in Inotek Pharmaceuticals Corp. by 70.9% in the second quarter. Adage Capital Partners GP L.L.C. now owns 470,000 shares of the company’s stock valued at $3,497,000 after buying an additional 195,000 shares in the last quarter. Polar Capital LLP purchased a new stake in Inotek Pharmaceuticals Corp. during the second quarter valued at about $504,000. Bridgeway Capital Management Inc. purchased a new stake in Inotek Pharmaceuticals Corp. during the second quarter valued at about $154,000. Finally, Citadel Advisors LLC purchased a new stake in Inotek Pharmaceuticals Corp. during the second quarter valued at about $126,000. 73.35% of the stock is currently owned by institutional investors and hedge funds.

Inotek Pharmaceuticals Corp. Company Profile

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

5 Day Chart for NASDAQ:ITEK

Receive News & Ratings for Inotek Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corp. and related companies with MarketBeat.com's FREE daily email newsletter.